These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

NEW YORK, NY, USA I March 19, 2025 I Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with ...

The dip came unexpectedly following the announcement of positive results from their respective studies on batoclimab for Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy ...

As I stated above, the company was able to report positive data from both its phase 3 study using batoclimab to target patients with Myasthenia Gravis and its phase 2b study using the same drug to ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial’s batoclimab ...